GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.96 USD | +2.14% |
|
+1.82% | -18.58% |
| 09/05 | Declaration of Voting Results by Gilead Sciences | CI |
| 09/05 | Declaration of Voting Results by Gilead Sciences | CI |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.92% | 0 M€ | +8.67% | ||
| 0.92% | 204 M€ | +10.54% | ||
| 0.87% | 3 M€ | +15.16% | - | |
| 0.87% | 4 M€ | -.--% | - | |
| 0.87% | 13 M€ | -.--% | - | |
| 0.83% | 0 M€ | +8.17% | ||
| 0.77% | 0 M€ | 0.00% | - | |
| 0.73% | 3,859 M€ | +18.82% | ||
| 0.73% | 469 M€ | -2.05% | ||
| 0.66% | 8 M€ | +5.48% | - | |
| 0.63% | 0 M€ | +8.33% | ||
| 0.62% | 2 M€ | +21.73% | - | |
| 0.60% | 92 M€ | +0.06% | - | |
| 0.57% | 0 M€ | +4.05% | - | |
| 0.52% | 5 M€ | -.--% | - | |
| 0.51% | 219 M€ | +17.17% | - | |
| 0.51% | 1,448 M€ | -.--% | - | |
| 0.50% | 330 M€ | -.--% | ||
| 0.47% | 2 M€ | +14.69% | - | |
| 0.44% | 0 M€ | +14.99% | ||
| 0.42% | 0 M€ | +6.22% | - | |
| 0.40% | 0 M€ | +9.18% | - | |
| 0.40% | 655 M€ | -.--% | - | |
| 0.40% | 273 M€ | -.--% | ||
| 0.40% | 1,174 M€ | +23.54% | ||
| 0.40% | 276 M€ | +11.40% | - | |
| 0.37% | 0 M€ | +18.09% | - | |
| 0.37% | 414 M€ | +11.90% | - | |
| 0.37% | 1,006 M€ | -.--% | ||
| 0.37% | 0 M€ | +12.85% | ||
| 0.36% | 1 M€ | +0.04% |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 82.18B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
